What is their price target now that $EBIO data failed and they don't see a way forward for this drug?“We are disappointed that isunakinra failed to meet its primary endpoint, and based on these overall results we see no immediate path forward in allergic conjunctivitis,” said Abbie Celniker, PhD, President and CEO of Eleven Biotherapeutics."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.